Clinical AI capabilities and diagnostic innovation for New Zealand & Oceania.
The Translyx Limited pipeline spans governed clinical AI workflow capabilities — under evaluation and development — and diagnostic innovation across AMR, sepsis, point-of-care testing, oncology, endocrine, cardiac, and precision medicine.
Translyx pipeline
A clinical AI observatory—not a shelf of finished products.
Capabilities are evaluated as governed workflows, with their maturity and limitations visible from the outset.
Pipeline capabilities are under evaluation or development and are not publicly launched products.
Capability field
Evaluation and development status
Diagnostic technology opportunities for New Zealand healthcare
Globally validated diagnostic and clinical technology areas Translyx is working to bring to New Zealand — across antimicrobial resistance, sepsis, point-of-care testing, oncology, endocrine, cardiac, and precision medicine.
Authorised partner solution
Aiforia Digital Pathology AI
Translyx is an authorised non-exclusive business partner of Aiforia Technologies Plc in New Zealand, representing Aiforia Clinical Suites and Aiforia Create Platform. Aiforia strengthens the oncology biomarkers, digital pathology, and precision medicine areas of this pipeline.
Diagnostic opportunity
Antibacterial Resistance
Antibacterial resistance remains an urgent public health concern even in New Zealand. While overall resistance rates here are lower than in some neighbouring regions, resistant strains are increasingly detected.
Examine opportunity
Diagnostic opportunity
Sepsis
Sepsis is a leading cause of serious illness and death, and it places a heavy burden on healthcare systems in New Zealand and internationally. In Aotearoa, sepsis is responsible for tens of thousands of infections annually.
Examine opportunity
Diagnostic opportunity
Oncology Biomarkers
Cancer remains a significant health challenge in New Zealand, with more than 30,000 people expected to be diagnosed each year in 2025. Accurate and timely biomarker testing is a cornerstone of modern oncology.
Examine opportunity
Diagnostic opportunity
Cardiac Biomarkers
Cardiovascular disease remains one of the leading causes of death and health burden in New Zealand. Cardiac biomarkers play a central role in diagnosing acute coronary syndromes and stratifying risk.
Examine opportunity
Diagnostic opportunity
Endocrine Biomarkers
Endocrine disorders such as diabetes, thyroid disease, and metabolic syndromes are highly prevalent in New Zealand. Accurate measurement of endocrine biomarkers is essential for diagnosing disease and guiding clinical interventions.
Examine opportunity
Diagnostic opportunity
Point of Care Testing
Point of care testing (POCT) is increasingly recognised as a vital part of modern healthcare delivery. POCT helps reduce turnaround times by providing diagnostic results near the patient.
Examine opportunityDiscuss the Translyx pipeline for your organisation.
Contact Translyx to discuss how pipeline capabilities and diagnostic innovation fit your healthcare or research priorities.